Tualang Honey Potentially Delay Deterioration in Haematological and Immunological Parameters in Asymptomatic, Treatment-naïve HIV-infected Patients
Main Article Content
Abstract
Introduction: This report aimed to assess the effects of administration of Tualang honey for six months duration on the haematological and immunological parameters in treatment-naïve HIV-infected patients who were asymptomatic. Methods: This was a randomised, controlled, open-labelled study. A total of 95 asymptomatic HIV-positive subjects with low CD4 counts of 250-600 cells/mm3 and not on antiretroviral therapy were recruited. Tualang honey was administered at 20 g each, once daily (HLD; total of 20 g honey), twice daily (HID; total of 40 g honey) or thrice daily (HHD; total of 60 g honey) for six months period. Control (CT) group did not receive any honey supplemen- tation. Haematological and immunological parameters were measured at baseline, three-month and six-month follow-up. The differences within the group (time effect) and between the groups (regardless of time) for all four groups were analysed using Repeated Measures ANOVA followed by a post-hoc test. Results: A significant reduction in total white blood cell, neutrophil and lymphocyte counts were observed at six-month follow-up in CT and HLD groups when compared to baseline. The immunological parameters showed similar trend of reduction in the CT and HLD groups. Meanwhile, the measured parameters were relatively maintained in HID and HHD groups at six-month period when compared to baseline. Conclusion: Tualang honey supplementation at intermediate and high doses for six months delay the deterioration of haematological and immunological parameters in asymptomatic, treatment-naïve HIV subjects.
Downloads
Article Details
References
Kathuria S, Bagga PK, Malhotra S. Hematological Manifestations in HIV Infected Patients and Correlation with CD4 Counts and Anti Retroviral Therapy. J Contemp Med Res. 2016;3(12):3495–8.
Bhardwaj S, Almaeen A, Ahmed Wani F, Thirunavukkarasu A. Hematologic derangements in HIV/AIDS patients and their relationship with the CD4 counts: a cross-sectional study. Int J Clin Exp Pathol. 2020;13(4):756–63.
Harding BN, Whitney BM, Nance RM, Ruderman SA, Crane HM, Burkholder G, et al. Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study. BMC Infect Dis. 2020;20:238.
Wagnew F, Eshetie S, Alebel A, Tesema C, Kibret GD, Gebrie A, et al. Burden of anemia and its association with HAART in HIV infected children in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2019;19:1032.
Gebreweld A, Fiseha T, Girma N, Haileslasie H, Gebretsadik D. Prevalence of cytopenia and its associated factors among HIV infected adults on highly active antiretroviral therapy at Mehal Meda Hospital, North Shewa Zone, Ethiopia. PLoS ONE. 2020;15(9):e0239215.
Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC Hematol. 2014;14(1):8.
Miedema F, Tesselaar K, Baarle D van, Borghans J, Hazenberg M, De Boer RJ. Immune activation and collateral damage in AIDS pathogenesis. Front Immunol. 2013;4:298.
Althoff K, Smit M, Reiss P, Justice A. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS. 2016;11(5):527–36.
Nemeth C, Bekhbat M, Neigh G. Neural effects of inflammation, cardiovascular disease, and HIV: parallel, perpendicular, or progressive? Neuroscience. 2015;302:165–73.
Massanella M, Chomont N, Fromentin R, Chomont N. Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr Opin HIV AIDS. 2016;11(2):234–41.
Ministry of Health Malaysia. Country Progress Report on HIV/AIDS 2019. Sector HIV/STI/Hepatitis C Ministry of Health, Disease Control Division. Malaysia: Ministry of Health Malaysia; 2019.
Kishore RK, Halim AS, Syazana MSN, Sirajudeen KNS. Tualang honey has higher phenolic content and greater radical scavenging activity compared with other honey sources. Nutr Res. 2011;31(4):322–5.
Vallianou NG, Gounari P, Skourtis A, Panagos J, Kazazis C. Honey and its anti-inflammatory, anti- bacterial and anti-oxidant properties. Gen Med Open Access. 2014;2.
Ahmad I, Jimenez H, Yaacob NS, Yusuf N. Tualang Honey Protects Keratinocytes from Ultraviolet Radiation-Induced Inflammation and DNA Damage. Photochem Photobiol. 2012;88(5):1198– 204.
Wan Yusuf WN, Wan Mohammad WMZ, Gan SH, Mustafa M, Abd Aziz CB, Sulaiman SA. Tualang honey ameliorates viral load, CD4 counts and improves quality of life in asymptomatic human immunodeficiency virus infected patients. J Tradit Complement Med. 2019;9(4):249–56.
Parinitha SS, Kulkarni MH. Haematological changes in HIV infection with correlation to CD4 cell count. Australas Med J. 2012;5(3):157–62.
Al-Waili NS. Effects of daily consumption of honey solution on hematological indices and blood levels of minerals and enzymes in normal individuals. J Med Food. 2003;6(2):135–40.
Ekata MO, Ezenwanne EB. Assessment study of some hematological indices in cholesterol-induced hyperlipidemic rabbits treated with Nigerian honey. J African Assoc Physiol Sci. 2016;4(1):48– 52.
Ahmed S, Sulaiman SA, Ibrahim M, Rasul A, Yasir M, Othman H. Effect of Daily Supplementation of Malaysian Jungle Tualang Honey and Australian/ New Zealand Manuka honey on Hematological and Some Biochemical Variables in Female Rats. Ann Life Sci. 2018;2(5):10–22.
De Santis GC, Brunetta DM, Vilar FC, Brandao RA, de Albernaz Muniz RZ, de Lima GMN, et al. Hematological abnormalities in HIV-infected patients. Int J Infect Dis. 2011;15(12):e808–11.
Mathews SE, Srivastava D, Yadav RB, Sharma A. Association of Hematological Profile of Human Immunodeficiency Virus-Positive Patients with Clinicoimmunologic Stages of the Disease. J Lab Physicians. 2013;5(01):34–7.
Zakaria Z, Abidin ZFZ, Gan SH, Hamid WZWA, Mohamed M. Effects of honey supplementation on safety profiles among postmenopausal breast cancer patients. J Taibah Univ Med Sci. 2018;13(6):535–40.
Heidari A, Zia HN, Amiri GH, Afsahi SH, Sarahroodi S. Has the natural raw honey any effect on HIV infection. Int J Pharm Res Bio-Science. 2012;1(5):205–10.
Katemba C, Muzoora C, Muwanguzi E, Mwambi B, Atuhairwe C, Taremwa IM. Hematological abnormalities in HIV-antiretroviral therapy naïve clients as seen at an immune suppression syndrome clinic at Mbarara regional referral hospital, southwestern Uganda. J Blood Med. 2018;9:105– 10.
Woldeamanuel GG, Wondimu DH. Prevalence of thrombocytopenia before and after initiation of HAART among HIV infected patients at black lion specialized hospital, Addis Ababa, Ethiopia: A cross sectional study. BMC Hematol. 2018;18(1):7–12.
David ML. The ESR in HIV: A Neglected Parameter? AIDS. 2010;24(18):2773.
Nwabuko C, Chukwuonye I, Nnoli M, Chuku A, Ejele O. The Relationship between Haematologic indices/Immunologic markers and HIV disease in Antiretroviral-naïve HIV seropositive Individuals in the Niger Delta Region of Nigeria. IOSR J Dent Med Sci. 2013;4(5):46–50.
Ndakotsu M, Salawu L, Durosinmi M. Relation between erythrocyte sedimentation rate, clinical and immune status in HIV-infected patients. Niger J Med. 2009;18(2):208–10.
Hameed MA, Waqas S. Physiological basis and clinical utility of erythrocyte sedimentation rate. Pak J Med Sci. 2006;22(2):214–8.
McBride JA, Striker R. Imbalance in the game of T cells: What can the CD4/CD8 T-cell ratio tell us about HIV and health? PLoS Pathog. 2017;13(11):e1006624.
Hughes RA, May MT, Tilling K, Taylor N, Wittkop L, Reiss P, et al. Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ : CD8+ ratio. Aids. 2018;32(10):1361–7.
Davy-Mendez T, Napravnik S, Zakharova O, Kuruc J, Gay C, Hicks CB, et al. Acute HIV infection and CD4/CD8 ratio normalization after antiretroviral therapy initiation. J Acquir Immune Defic Syndr. 2018;79(4):510–8.
Frosch AE, Odumade OA, Taylor JJ, Ireland K, Ayodo G, Ondigo B, et al. Decrease in Numbers of Naive and Resting B Cells in HIV-Infected Kenyan Adults Leads to a Proportional Increase in Total and Plasmodium falciparum– Specific Atypical Memory B Cells . J Immunol. 2017;198(12):4629– 38.
Moir S, Fauci AS. B-cell responses to HIV infection. Immunol Rev. 2017;275(1):33-48.
Sweiss NJ, Salloum R, Ghandi S, Alegre ML, Sawaqed R, Badaracco M, et al. Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations. PLoS One. 2010;5(2):e9088.
Lucar O, Keith Reeves R, Jost S. A natural impact: NK cells at the intersection of cancer and HIV disease. Front Immunol. 2019;10:1850.
Flórez-Álvarez L, Hernandez JC, Zapata W. NK cells in HIV-1 infection: From basic science to vaccine strategies. Front Immunol. 2018;9(OCT):2290.
Ota M, Ishiuchi K, Xu X, Minami M, Nagachi Y, Yagi-Utsumi M, et al. The immunostimulatory effects and chemical characteristics of heated honey. J Ethnopharmacol. 2019;228:11–7.
Duddukuri GR, Rao DN, Athota RR. Suppressive effect of honey on antigen/mitogen stimulated murine T cell proliferation. Pharm Biol. 2002;40(1):39–44.
Aw Yong PY, Islam F, Harith HH, Israf DA, Tan JW and Tham CL. The potential use of honey as a remedy for allergic diseases: a mini review. Front Pharmacol. 2021;11:599080.